Zobrazeno 1 - 5
of 5
pro vyhledávání: '"Margaux Delforge"'
Autor:
Daniel Re, Barbara Seitz-Polski, Vesna Brglez, Michel Carles, Daisy Graça, Sylvia Benzaken, Stéphane Liguori, Khaled Zahreddine, Margaux Delforge, Béatrice Bailly-Maitre, Benjamin Verrière, Emmanuel Chamorey, Jérôme Barrière
Publikováno v:
Nature Communications, Vol 13, Iss 1, Pp 1-9 (2022)
Vaccination is effective in preventing severe COVID-19 symptoms. Here the authors monitor patients with hematopoietic malignancy to find the third dose of the mRNA vaccine, BNT162b2, only boosts the humoral immunity in those showing responses to 2nd
Externí odkaz:
https://doaj.org/article/8808f98f7cc44e10b49d3f99b59f6efc
Autor:
Daniel Re, Barbara Seitz-Polski, Vesna Brglez, Michel Carles, Daisy Graça, Sylvia Benzaken, Stéphane Liguori, Khaled Zahreddine, Margaux Delforge, Béatrice Bailly-Maitre, Benjamin Verrière, Emmanuel Chamorey, Jérôme Barrière
Publikováno v:
Nature communications. 13(1)
Patients with hematological malignancies have impaired immune response after two doses of BNT162b2 (Pfizer/BioNTech) vaccine against SARS-CoV-2. Here, in this observational study (registration number HDH F20210324145532), we measure SARS-CoV-2 anti-S
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::b1859377e6726fcd867e7717529db0cf
https://pubmed.ncbi.nlm.nih.gov/35165284
https://pubmed.ncbi.nlm.nih.gov/35165284
Autor:
Daniel Re, Jérôme Barrière, Frederic Peyrade, Axel Chaminade, Emmanuel Chamorey, Lauris Gastaud, Benjamin Verrière, Emmanuel Petit, Margaux Delforge
Publikováno v:
Leukemialymphoma. 62(13)
Patients suffering from hematological malignancies (HMs) are at high risk of dying from infectious disease and specifically of coronavirus disease of 2019 (COVID 19) [1,2] or of developing chronic ...
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::b7aaf60e45c77fa5b95cc68c9a2f36f0
https://pubmed.ncbi.nlm.nih.gov/34308748
https://pubmed.ncbi.nlm.nih.gov/34308748
Autor:
Daniel Re, Barbara Seitz-Polski, Michel Carles, Vesna Brglez, Daisy Graça, Sylvia Benzaken, Stéphane Liguori, Khaled Zahreddine, Margaux Delforge, Benjamin Verrière, Emmanuel Chamorey, Barrière Jérôme
BACKGROUNDImmunocompromised patients such as patients with hematological malignancies have impaired immune response to two doses of BNT162b2 (Pfizer / BioNtech) vaccine against SARS-CoV-2. Evaluation of a repeated immune stimulation with a third vacc
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::fac60729ee6dbd67fa267863d29e09ad
https://doi.org/10.1101/2021.07.18.21260669
https://doi.org/10.1101/2021.07.18.21260669
Autor:
Margaux Delforge, Emmanuel Chamorey, Barbara Seitz-Polski, Benjamin Verrière, Stéphane Liguori, Vesna Brglez, Michel Carles, Khaled Zahreddine, Daisy Graça, Daniel Re, Jérôme Barrière, Sylvia Benzaken
BACKGROUND: Immunocompromised patients such as patients with hematological malignancies have impaired immune response to two doses of BNT162b2 (Pfizer / BioNtech) vaccine against SARS-CoV-2. Evaluation of a repeated immune stimulation with a third va
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::1e1288e5c7cfc7bca9e5addb5b0ec8a9
https://doi.org/10.21203/rs.3.rs-727941/v1
https://doi.org/10.21203/rs.3.rs-727941/v1